Indications
Oncaspar is indicated as a component of antineoplastic combination therapy in acute lymphoblastic leukaemia (ALL) in paediatric patients from birth to 18 years, and adult patients.
Composition
- Active substance
- pegaspargase
Official product information
The European public assessment report holds the summary of product characteristics and the package leaflet in every EU language.
Prognia shows this product information for reference and learning. It is not treatment advice and can lag behind the official text. Always check the current product information and local protocols before prescribing.
At a glance
- Medicine
- Oncaspar
- Active substance
- pegaspargase
- ATC code
- L01XX24
- Therapeutic area
- Precursor Cell Lymphoblastic Leukemia-Lymphoma
- Marketing authorisation holder
- Les Laboratoires Servier
- Status
- Authorised